SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma
This study is testing a new medication called mirdametinib to see how well it treats low-grade gliomas, which are slow-growing brain or spinal cord tumors. The drug works by blocking specific signals that tell tumor cells to grow, offering a potential new treatment option for young patients.
This trial is for children, adolescents, and young adults between the ages of 2 and 25 who have been diagnosed with this type of tumor. To join, you must have a tumor sample available for testing and meet specific health requirements regarding your digestion, liver, and lung function.
Participants will receive the study medication, mirdametinib, and undergo regular monitoring by the medical team to see how their tumor responds. The doctors will track your progress closely to ensure the treatment is safe and effective for your specific condition.
The study is currently recruiting patients and is taking place at a medical center in Memphis, Tennessee. You can talk to your doctor or the study team to see if this location works for you.
- 1Mirdametinib is designed to cross into the brain to target tumor cells directly.
- 2The study is open to patients aged 2 to 25 with low-grade gliomas.
- 3Researchers are carefully screening participants to make sure the drug is safe for their specific health needs.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.